Parlodel Drug Interactions

Observed interactions to be considered: CYP3A4 substrates/inhibitors: Bromocriptine is both a substrate and an inhibitor of CYP3A4 (see Pharmacology under Actions). Caution should therefore be used when co-administering drugs which are strong inhibitors and/or substrates of this enzyme (azole antimycotics, HIV protease inhibitors). The concomitant use of macrolide antibiotics such as erythromycin or josamycin, was shown to increase the plasma levels of bromocriptine. The concomitant treatment of acromegalic patients with bromocriptine and octreotide led to increased plasma levels of bromocriptine.
Sympathomimetic drugs: Co-administration of sympathomimetics such as phenylpropanolamine and bromocriptine may lead to hypertension and severe headache (see Precautions).
Sumatriptan: Co-administration of sumatriptan may potentiate the risk of vasospastic reactions due to additive pharmacological effects.
Ergot alkaloids: Co-administration may increase the dopamine stimulant activity and lead to dopaminergic side effects such as headache, nausea, vomiting (see Precautions).
Dopamine receptor antagonists: Since Parlodel exerts its therapeutic effect by stimulating central dopamine receptors, dopamine antagonists such as antipsychotics (phenothiazines, butyrophenones and thioxanthenes), but also metoclopramide and domperidone may reduce its activity.
Alcohol: The tolerability to Parlodel may be reduced by alcohol.